Brain stimulation boosts therapy outcomes for OCD in clinical trial

A new study published in Nature Mental Health suggests that combining brain stimulation with a common psychological treatment may enhance outcomes for people with obsessive-compulsive disorder. Researchers found that patients who received transcranial direct current stimulation during exposure-based therapy showed greater reductions in OCD symptoms compared to those who received therapy alone. The findings also point to subtle changes in brain activity that could help explain individual differences in treatment response.

Obsessive-compulsive disorder, or OCD, is a mental health condition characterized by the presence of obsessions, compulsions, or both. Obsessions are unwanted, intrusive thoughts, images, or urges that cause significant distress or anxiety. These might include fears of contamination, fears of harming others, concerns about symmetry or order, or intrusive taboo thoughts. Compulsions are repetitive behaviors or mental acts that individuals feel driven to perform in response to an obsession, often in an attempt to reduce the distress or prevent a feared outcome. Common compulsions include excessive cleaning or handwashing, checking doors or appliances, counting, or repeating phrases silently.

OCD is more than a preference for cleanliness or organization—it can be deeply distressing and disruptive, interfering with daily life, work, and relationships. Symptoms often follow a cycle in which a distressing thought (obsession) triggers anxiety, prompting the person to engage in a ritual (compulsion) to try to neutralize the anxiety or prevent something bad from happening. While compulsive behaviors may provide temporary relief, the obsessions typically return, reinforcing the cycle.

The condition is estimated to affect around 1.3% of the global population over the course of a lifetime. It tends to develop in childhood or early adulthood and often persists without treatment. OCD is associated with high levels of distress and can severely impair quality of life.

Psychological treatment usually takes the form of exposure and response prevention (ERP), a type of cognitive behavioral therapy. ERP works by helping people gradually confront the thoughts, images, or situations that trigger their obsessions, without performing their usual compulsions. Over time, this process helps reduce anxiety and weakens the obsessive-compulsive cycle.

Free daily newsletter

While ERP is widely considered one of the most effective treatments for OCD, its success is variable. Some people show marked improvement, but many continue to experience symptoms. To improve treatment outcomes, the research team explored the use of transcranial direct current stimulation, or tDCS. This technique delivers a weak electrical current to the brain through electrodes placed on the scalp.

Some evidence suggests that tDCS targeting the medial prefrontal cortex—a brain region involved in learning and unlearning fear—might enhance a process called inhibitory learning. This process is thought to underlie the success of exposure-based therapies by helping people learn that previously feared situations are no longer dangerous.

The researchers conducted a randomized, double-blind, controlled trial at the Shanghai Mental Health Center to test whether applying tDCS during exposure and response prevention therapy could improve its effectiveness. They focused specifically on individuals whose OCD symptoms centered around contamination fears and cleaning rituals, a common and well-defined subtype that allowed for more consistent exposure sessions.

The study enrolled 53 patients between the ages of 18 and 50 who met diagnostic criteria for OCD and had moderate to severe symptoms. Participants were randomly assigned to one of two groups: one received active tDCS during exposure therapy, while the other received a sham version that mimicked the sensation of stimulation without delivering current. Neither the patients nor the therapists knew which type of stimulation was being used. All participants completed ten therapy sessions over eight weeks.

During the treatment sessions, tDCS was applied for 20 minutes at the beginning of each exposure session using a configuration that targeted the medial prefrontal cortex. High-definition tDCS was used to deliver a consistent 1.5 milliamp current in the active group, while the sham group received a brief initial current to mimic the sensation but no sustained stimulation.

To assess treatment outcomes, the researchers used the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS), a well-established measure of OCD severity. They recorded scores at baseline and after the first, fourth, and eighth treatment sessions. The primary outcome was the percentage reduction in Y-BOCS scores from baseline. Additional assessments included EEG recordings to measure brain activity and magnetic resonance imaging (MRI) to model how the electrical field from tDCS was distributed across each individual’s brain.

The results showed that both groups improved over time, but those receiving active tDCS during therapy had significantly greater symptom reduction after four and eight sessions. By the end of the treatment period, the active group showed an average symptom reduction of 38%, compared to 28% in the sham group. Moreover, 62% of patients in the active group met the study’s threshold for a treatment response—defined as a 35% or greater reduction in symptoms—compared to 30% in the sham group.

These differences suggest that the combination of brain stimulation and therapy may enhance the learning processes that help reduce OCD symptoms. Importantly, no moderate or severe side effects were reported in either group, and mild side effects were similar between groups, indicating that the combined approach appears to be safe.

To better understand why some individuals responded more strongly to treatment, the researchers analyzed brain activity using electroencephalography (EEG). Specifically, they focused on patterns known as EEG microstates—brief periods during which the brain’s electrical activity remains stable. These microstates are thought to reflect different functional networks in the brain.

After the first treatment session, the researchers found a small increase in one type of EEG microstate (MS-B) in the active tDCS group compared to the sham group. They also found a weak correlation between changes in another microstate (MS-A) and treatment response, suggesting that early changes in brain network activity may be related to symptom improvement, though the finding did not reach strong statistical significance.

The team also used MRI data to create personalized models of how the electrical current from tDCS spread through each participant’s brain. This modeling confirmed that current strength varied across individuals, largely due to differences in skull thickness and brain anatomy. However, the researchers did not find a consistent relationship between the modeled electric field strength and treatment response, which suggests that other factors may play a more important role in how tDCS affects the brain.

While the findings support the potential benefits of combining tDCS with exposure therapy, the study has some limitations. The sample included only patients with contamination-related OCD, so it is unclear whether the results apply to other symptom types. The EEG findings were exploratory and only marginally significant, and the study was not designed to determine exactly how tDCS changes brain activity during therapy. More research with larger and more diverse samples will be needed to confirm and extend these findings.

The study, “Transcranial direct current stimulation enhances exposure–response prevention for contamination-related OCD: a randomized clinical trial,” was authored by Jian Gao, Wenjun Jia, Puzhe Li, Hui zhao, Liangjun Lin, Meiling Chen, Rui Gao, Xitong Liu, Tianran Zhang, Wenqing Zhao, Lian Gu, Jiejing Yu, Mu-Ming Poo, Dan J. Stein, Jianfeng Luo, Jian Jiang, and Zhen Wang.